8-K: Oramed Pharmaceuticals Amends Bylaws, Extends Scilex Debt Payment

Oramed Pharmaceuticals Inc. announced amendments to its bylaws regarding stockholder action by written consent and an extension for Scilex Holding Company's payment obligations on outstanding promissory notes.

Summary

• Oramed Pharmaceuticals Inc. has updated its Fifth Amended and Restated Bylaws, effective June 25, 2026, to refine procedures for stockholder action by written consent.
• Key changes to the bylaws include: if the Board of Directors does not fix a record date for stockholder action by written consent, it will be fixed according to Delaware General Corporation Law.
• The bylaws now eliminate a previous requirement for stockholders requesting a record date to provide detailed information about proposed actions and solicitation plans.
• The effectiveness of stockholder consents has been revised to require delivery to the Company within 60 days of the first consent being delivered.
• Additionally, Oramed has entered into an Extension Agreement with Scilex Holding Company, further extending Scilex's payment obligations on outstanding promissory notes.
• As of June 30, 2026, Scilex owes Oramed approximately $29.5 million on the Tranche A Note and approximately $6.7 million on the Tranche B Note.
• Under the new agreement, Scilex made a $0.5 million cash payment on June 25, 2026.
• Scilex is scheduled to pay $5 million by July 31, 2026, and the remaining balance by September 30, 2026.
• If Scilex fails to meet the September 30, 2026 deadline, the first $1.5 million received will be considered a non-refundable extension fee, and the obligations will remain outstanding.
• In case of default by the deadline, Scilex may satisfy remaining obligations through the delivery of Scilex common stock, subject to agreed-upon terms and an effective registration statement.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the extension of significant debt obligations and the potential for a portion of the debt to be converted into a non-refundable fee, although the bylaw amendments are neutral to positive.

Positives

• The company has clarified and streamlined its bylaws regarding stockholder actions, potentially improving corporate governance efficiency.
• An initial cash payment of $0.5 million has already been received from Scilex.
• A structured payment plan with defined deadlines for Scilex's obligations provides a clearer path to potential recovery of funds.
• The agreement includes provisions for Scilex to potentially satisfy remaining debt with shares, offering an alternative recovery mechanism if cash payments are insufficient.

Negatives

• Scilex Holding Company has outstanding payment obligations totaling approximately $36.2 million as of June 30, 2026, on two promissory notes.
• The company has agreed to further extensions for these significant payment obligations.
• There is a risk that Scilex may not meet the final payment deadline of September 30, 2026, which could lead to a portion of payments being retained as an extension fee rather than applied to the debt.
• If Scilex defaults on cash payments, the company may receive Scilex stock, the value of which is subject to market fluctuations and agreement on terms.

Risks

• The primary risk is Scilex's potential failure to meet the extended payment deadlines, which could result in the company retaining a portion of payments as an extension fee and the debt remaining outstanding.
• If Scilex defaults on cash payments by September 30, 2026, the company's recovery of the full outstanding amount may depend on the valuation and terms of Scilex shares to be delivered.
• The amended bylaws introduce a 60-day window for the effectiveness of stockholder consents, which could impact the timing and certainty of corporate actions taken by written consent.

Future Outlook

The future outlook is contingent on Scilex's ability to meet the revised payment schedule for its outstanding obligations to Oramed. The company has also updated its bylaws, which may affect future stockholder actions.

Industry Context

StockSavvy.ai notes that amendments to corporate bylaws are common as companies evolve, aiming to improve governance and shareholder engagement processes. The extension of debt payment terms, particularly between related entities like Oramed and Scilex, highlights the ongoing financial dynamics and potential liquidity challenges within the biotechnology sector.

Corporate Governance

Related Party Transactions

• The Extension Agreement and the outstanding promissory notes (Tranche A and Tranche B) between Oramed Pharmaceuticals Inc. and Scilex Holding Company represent related party transactions, given their interconnectedness.

Stakeholder Impact

• Shareholders: The bylaw amendments may impact the process and timing of stockholder-initiated actions. The extension of debt repayment from Scilex could affect the company's cash flow and potential recovery of funds.
• Creditors: The extension of Scilex's payment obligations may impact Oramed's immediate liquidity and its ability to utilize those funds.
• Management: The bylaw changes may require adjustments in how management handles stockholder communications and consent processes.

Next Steps

• Scilex is expected to make a $5 million payment by July 31, 2026.
• Scilex is expected to pay the remaining balance by September 30, 2026, or deliver shares of common stock.
• The Board of Directors will continue to oversee the company's operations and governance in accordance with the amended bylaws.

Key Dates

Recommendation

The filing presents a mixed picture. While the bylaw amendments are a positive step for corporate governance, the significant extension of debt repayment from Scilex, coupled with the risk of a portion of the debt becoming a non-refundable fee, introduces uncertainty regarding the recovery of substantial funds. This warrants a 'hold' recommendation pending further clarity on Scilex's payment performance.

Keywords

Oramed Pharmaceuticals, Scilex Holding Company, Bylaws Amendment, Promissory Note, Debt Extension, Stockholder Action, Corporate Governance, SEC Filing, Form 8-K